![]() |
|
|
Vol. 298, Issue 3, 894-899, September 2001
Department of Drug Delivery Research, Graduate School of
Pharmaceutical Sciences (Y.Y., N.K., T.N., M.N., Y.T., M.H.), and
Department of Pathology and Tumor Biology, Graduate School of Medicine
(R.T.), Kyoto University, Sakyo-ku, Kyoto, Japan.
Our previous study demonstrated that the combination of mannosylated
superoxide dismutase (Man-SOD) and succinylated catalase (Suc-CAT),
both of which are designed to be targeted to liver nonparenchymal
cells, is a promising approach to prevent the initial phase of hepatic
ischemia/reperfusion injury induced by occlusion of the portal vein for
30 min followed by a 1-h reperfusion in mice. In this study, the
preventive effects of these agents were examined on late-phase injury
mediated by infiltrating neutrophils, a more severe condition than the
initial one. Administration of Suc-CAT alone or with Man-SOD to mice
undergoing hepatic ischemia/reperfusion significantly suppressed the
expression of intercellular adhesion molecule-1 along the hepatic
sinusoid and prevented neutrophil infiltration in the liver. Man-SOD
and Suc-CAT also prevented the increase in plasma glutamic pyruvic
transaminase and glutamic oxaloacetic transaminase activities after
reperfusion lasting 3 and 6 h. Histological evaluation of liver
tissues confirmed the efficacy of this treatment, suggesting that these
SOD and catalase derivatives have the ability to suppress
neutrophil-induced hepatic injury. These results demonstrate that
targeted delivery of antioxidant enzymes to liver nonparenchymal cells
is a promising approach to reducing the reactive oxygen species
produced by Kupffer cells and neutrophils infiltrating into the tissue.
Since Suc-CAT is partially taken up by hepatocytes via a
catalase-specific uptake mechanism, such a fraction could also be
involved in its preventive effect against the injury.
This article has been cited by other articles:
![]() |
K. Hyoudou, M. Nishikawa, Y. Kobayashi, Y. Kuramoto, F. Yamashita, and M. Hashida Analysis of In Vivo Nuclear Factor-{kappa}B Activation during Liver Inflammation in Mice: Prevention by Catalase Delivery Mol. Pharmacol., February 1, 2007; 71(2): 446 - 453. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pacher, J. S. Beckman, and L. Liaudet Nitric Oxide and Peroxynitrite in Health and Disease Physiol Rev, January 1, 2007; 87(1): 315 - 424. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Gordon, F. Li, X. Zhang, W. Wang, X. Zhao, and A. Nayyar The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals J. Leukoc. Biol., December 1, 2005; 78(6): 1265 - 1272. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. N. Hines, J. M. Hoffman, H. Scheerens, B. J. Day, H. Harada, K. P. Pavlick, S. Bharwani, R. Wolf, B. Gao, S. Flores, et al. Regulation of postischemic liver injury following different durations of ischemia Am J Physiol Gastrointest Liver Physiol, March 1, 2003; 284(3): G536 - G545. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Jaeschke Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning Am J Physiol Gastrointest Liver Physiol, January 1, 2003; 284(1): G15 - G26. [Abstract] [Full Text] [PDF] |
||||